Patenting Monoclonal Antibodies in China: Criteria on Novelty and Inventiveness Examination

'Patenting Monoclonal Antibodies in China: Criteria on Novelty and Inventiveness Examination'was an article published on Lung Tin IP Newsletter of January, 2021.

Please click the link below on this page for further reading.

Patenting Monoclonal Antibodies in China: Criteria on Novelty and Inventiveness Examination